Summary

Glycemic management in type 2 diabetes mellitus (T2DM) has become increasingly complex and, to some extent, controversial. A widening array of pharmacological agents [Nyenwe EA et al. Metabolism 2011; Blonde L. Am J Med 2010; Bergenstal RM et al. Am J Med 2010] has raised concerns about their potential adverse effects, as well as new uncertainties about the effects of intensive glycemic control on macrovascular complications [Yudkin JS et al. Lancet 2011]. This article reviews key points from the new Position Statement from the American Diabetes Association and the European Association for the Study of Diabetes [Inzucchi SE et al. Diabetes Care 2012; Inzucchi SE et al. Diabetologia 2012].